Description
Nilotinib is prescribed to manage specific forms of chronic myeloid leukemia (CML), a type of white blood cell cancer. It is utilized for individuals whose CML hasn’t responded well to imatinib (Gleevec) or for those who cannot tolerate imatinib treatment. This medication belongs to the kinase inhibitor class and functions by inhibiting the activity of an abnormal protein that triggers the multiplication of cancer cells. This action serves to halt or impede the proliferation of cancerous cells.